LGND vs. ARCT, PRAX, NRIX, CMPS, TVTX, HALO, IONS, MDGL, ALKS, and FOLD
Should you be buying Ligand Pharmaceuticals stock or one of its competitors? The main competitors of Ligand Pharmaceuticals include Arcturus Therapeutics (ARCT), Praxis Precision Medicines (PRAX), Nurix Therapeutics (NRIX), COMPASS Pathways (CMPS), Travere Therapeutics (TVTX), Halozyme Therapeutics (HALO), Ionis Pharmaceuticals (IONS), Madrigal Pharmaceuticals (MDGL), Alkermes (ALKS), and Amicus Therapeutics (FOLD). These companies are all part of the "medical" sector.
Arcturus Therapeutics (NASDAQ:ARCT) and Ligand Pharmaceuticals (NASDAQ:LGND) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, media sentiment, community ranking, profitability, risk and earnings.
Ligand Pharmaceuticals received 103 more outperform votes than Arcturus Therapeutics when rated by MarketBeat users. Likewise, 69.96% of users gave Ligand Pharmaceuticals an outperform vote while only 65.44% of users gave Arcturus Therapeutics an outperform vote.
In the previous week, Arcturus Therapeutics had 7 more articles in the media than Ligand Pharmaceuticals. MarketBeat recorded 9 mentions for Arcturus Therapeutics and 2 mentions for Ligand Pharmaceuticals. Arcturus Therapeutics' average media sentiment score of 1.21 beat Ligand Pharmaceuticals' score of 0.99 indicating that Ligand Pharmaceuticals is being referred to more favorably in the news media.
94.5% of Arcturus Therapeutics shares are owned by institutional investors. Comparatively, 91.3% of Ligand Pharmaceuticals shares are owned by institutional investors. 13.8% of Arcturus Therapeutics shares are owned by insiders. Comparatively, 5.9% of Ligand Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Arcturus Therapeutics currently has a consensus price target of $64.86, suggesting a potential upside of 67.11%. Ligand Pharmaceuticals has a consensus price target of $116.33, suggesting a potential upside of 36.78%. Given Ligand Pharmaceuticals' higher probable upside, equities research analysts clearly believe Arcturus Therapeutics is more favorable than Ligand Pharmaceuticals.
Ligand Pharmaceuticals has a net margin of 79.30% compared to Ligand Pharmaceuticals' net margin of -81.59%. Arcturus Therapeutics' return on equity of 8.52% beat Ligand Pharmaceuticals' return on equity.
Arcturus Therapeutics has a beta of 2.65, suggesting that its stock price is 165% more volatile than the S&P 500. Comparatively, Ligand Pharmaceuticals has a beta of 1.01, suggesting that its stock price is 1% more volatile than the S&P 500.
Ligand Pharmaceuticals has higher revenue and earnings than Arcturus Therapeutics. Arcturus Therapeutics is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Ligand Pharmaceuticals beats Arcturus Therapeutics on 11 of the 17 factors compared between the two stocks.
Get Ligand Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for LGND and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LGND and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ligand Pharmaceuticals Competitors List
Related Companies and Tools
